Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Current Leases (2019 - 2025)

Standard Biotools (LAB) has disclosed Current Leases for 7 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 14.23% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2025, up 14.23% year-over-year, with the annual reading at $5.5 million for FY2025, 14.23% up from the prior year.
  • Current Leases for Q4 2025 was $5.5 million at Standard Biotools, up from $5.1 million in the prior quarter.
  • The five-year high for Current Leases was $6.3 million in Q1 2025, with the low at $2.9 million in Q3 2021.
  • Average Current Leases over 5 years is $4.3 million, with a median of $3.9 million recorded in 2023.
  • The sharpest move saw Current Leases soared 155.27% in 2021, then decreased 16.48% in 2025.
  • Over 5 years, Current Leases stood at $3.1 million in 2021, then grew by 20.6% to $3.7 million in 2022, then grew by 17.41% to $4.3 million in 2023, then increased by 11.17% to $4.8 million in 2024, then increased by 14.23% to $5.5 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $5.5 million, $5.1 million, and $5.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.